Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Allogene Therapeutics (ALLO) has entered into 5-year collaboration agreement with The University of Texas MD Anderson Cancer Center for preclinical and clinical investigation of AlloCAR T candidates for hematologic and solid tumors.Under the agreement, MD Anderson and Allogene will colla...
Clinical and Translational Research Collaboration Will Evaluate Multiple AlloCAR T Candidates Across the Allogene Portfolio Targeting Multiple Tumor Types SOUTH SAN FRANCISCO, Calif. and HOUSTON, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a cli...
Sarepta has a diversified portfolio of 43 programs including 27 gene therapy and 14 RNA programs. The pipeline is spread between discovery (21) and commercial (2) medicines. The current valuation for Sarepta is comparable to the group of 6 gene therapy companies acquired between 2017 ...
The best-rated mid-cap sector is consumer goods. The top scoring industry is specialty retail. Churchill Downs, Simply Good Foods, and Wolverine World Wide are among the best scoring stocks this week. For further details see: The Top Mid-Cap Stocks To Target On Down Days...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in ...
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in...
Genomic medicine, the next major biotech era, is primarily pre-commercial though a few medicines have been approved. The list of FDA-approved cellular and gene therapy products did increase in July when the second Kite Pharma ( GILD ) cell therapy - Tecartus - was approved for relapsed/refract...
Allogene Therapeutics, Inc. (ALLO) Q2 2020 Earnings Conference Call August 5, 2020 8:30 AM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive Vice President-Re...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...